GlassScriptPhysician profile
Amelia Quiz
NPI 1568671220
$4,650.97
in general payments reported to CMS, 2019-2025
27 companies · $733 in 2025
The $733 reported for 2025 was more than what 79% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $859 · 2022: $988 · 2023: $844 · 2024: $1,227 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,803.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $943.13 | 2021-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $529.94 | 2022-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $501.57 | 2022-2025 | |
| Lilly USA, LLC | $443.37 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $361.89 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $358.23 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.78 | 2021-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $157.60 | 2021-2025 | Rexulti |
| Abbott Laboratories | $135.39 | 2023-2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $121.60 | 2024 | Voquezna |
| Lundbeck LLC | $96.36 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.52 | 2021-2025 | Jardiance |
| Exact Sciences Corporation | $91.18 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $87.95 | 2022-2023 | Belsomra, Steglatro, Verquvo |
| Viatris Specialty LLC | $82.97 | 2025 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69.68 | 2021-2024 | |
| Paratek Pharmaceuticals, INC. | $63.43 | 2023-2024 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $61.36 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $50.88 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $39.82 | 2022 | |
| Esperion Therapeutics, INC. | $32.61 | 2021 | |
| Novo Nordisk INC | $30.63 | 2024 | Wegovy |
| Avanir Pharmaceuticals, INC. | $29.54 | 2021 | |
| Amarin Pharma, INC. | $24.20 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.34 | 2024 | Xifaxan, Trulance |
| Mylan Specialty L.P. | $15.47 | 2024 | Yupelri |
| Currax Pharmaceuticals LLC | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Quiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.